当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Laoues Mostafa
The aim of our study is to determine the most suitable system for the better dose distribution of the brachytherapy treatment of cervix cancer by the Cesium-137, and recommended for use in Algeria anti-cancer centers. It is mainly concentrated on clinical and dosimetrical aspects in brachytherapy treatment of cervix cancer, through notably, the doses distribution while using, the Manchester method (prescription at the A point) and the method recommended by the ICRU 38 (International Commission one Radiation Units and measurements, Report N°38) that give the prescription of the dose in terms of treated volume. We used these methods of doses prescription, for the choice of the reference isodose, and also to estimate received doses in organs at risk. The gotten results show that both methods have significant differences in the choice of the reference isodose three centers. However, the method recommended by the ICRU-38 is best approximate to the clinical reality for the choice of the reference isodose. Both methods show that received doses in organs at risk are within tolerance. Despite this, the radiation therapist role for this type of treatment is still important.